Cellectis, a biotechnology company specializing in gene editing, has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its CAR-T cell therapy, lasmecabtagene timgedleucel (lasme-cel). This therapy targets patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) and is recognized for its potential to address significant unmet medical needs in this patient population. The RMAT designation is based on encouraging results from the Phase 1 BALLI-01 trial, which demonstrated promising efficacy and a manageable safety profile. Cellectis plans to present final Phase 1 data at the upcoming European Hematology Association Congress. André Choulika, CEO of Cellectis, emphasized the importance of this designation in facilitating discussions with the FDA as the company advances lasme-cel through its pivotal program. The BALLI-01 Phase 2 trial is currently open for patient enrollment, indicating a significant step forward in the development of this innovative therapy.